Electroencephalographic changes in purified pharmaceutical cannabidiol therapy
Aline Herlopian1, James R Barnett2, Fábio A Nascimento3
1Comprehensive Epilepsy Center, Department of Neurology, Yale University, 15 York St, LCI-7, New Haven, CT 06510, USA.
Epilepsy & Behavior : E&B
|January 25, 2022
Summary
Purified pharmaceutical cannabidiol (CBD) treatment showed significant electroencephalographic (EEG) changes in most pediatric epilepsy patients. While EEG improvements were observed, a direct link between these specific changes and clinical outcomes requires further investigation.
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Pediatric-onset refractory epilepsy presents significant challenges in management.
- Cannabidiol (CBD) is being investigated for its therapeutic potential in epilepsy.
Purpose of the Study:
- To evaluate electroencephalographic (EEG) changes in patients receiving purified pharmaceutical cannabidiol (CBD).
Main Methods:
- Retrospective analysis of 104 EEG studies from 52 pediatric patients with refractory epilepsy treated with CBD.
- Assessment of EEG background, interictal epileptiform discharges (IEDs), ictal findings, and sleep architecture.
Main Results:
- 88.4% of patients exhibited EEG changes post-CBD treatment.
- Significant alterations were noted in EEG background (89%), IEDs (74%), and ictal findings (46%).
- Electrographic improvement occurred in 70% of patients with EEG changes, with 83% showing reduced seizure frequency.
Conclusions:
- Purified pharmaceutical CBD is associated with notable electrographic changes in pediatric epilepsy patients.
- While EEG alterations and seizure frequency reduction were observed, a definitive association between specific electrographic findings and clinical outcomes was not established.
